MOH committed to keeping medicines affordable
11 June 2013
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
30 May 2013, Straits Times
Drug subsidy puzzle
MY MOTHER, who is a subsidised patient, was diagnosed with stage 4 lung cancer at the National University Hospital (NUH).
She was prescribed a daily dose of cancer drug Iressa, which is non-subsidised and costs $107.50 per pill.
The non-subsidised price for each pill at the National Cancer Centre Singapore (NCCS) is $98.44 (subsidised patients pay $92).
A check with NUH revealed that Iressa is more expensive there because of the lower volume of patients compared to the number at NCCS.
No explanation was offered for why the drug is not subsidised at NUH.
The separate procurement of drugs has not benefited patients at NUH.
Why isn't the Health Ministry buying drugs in bulk and redistributing them to hospitals to reap benefits from economies of scale?
Both NUH and NCCS are public health-care institutions, so why is Iressa subsidised in one and not the other?
Lim Chee Chuan
---------------------------------
Reply from MOH
11 Jun 2013, Straits Times
MOH committed to keeping medicines affordable
MR LIM Chee Chuan ("Drug subsidy puzzle"; May 30) asked about subsidies for the cancer drug Gefitinib (brand name Iressa).
Iressa is a non-standard drug and hence not subsidised at both the National University Hospital and National Cancer Centre Singapore.
Different institutions may have different pricing as their costs may differ.
We agree with Mr Lim on the benefits of bulk purchasing, and Iressa has been centrally purchased through the public health-care clusters' Group Procurement Office since 2009.
Unfortunately, the sole supplier of Iressa in Singapore did not participate in the bulk purchasing effort last year, resulting in the hospitals having to purchase the drug individually.
We will continue to explore the possibility of bulk purchasing of Iressa and other drugs.
We would like to clarify that the Ministry of Health (MOH) absorbs the Goods and Services Tax for treatment received by all subsidised patients, such as Mr Lim's mother.
The MOH is committed to keeping drug costs affordable, through bulk purchasing of drugs, subsidies and financial assistance.
Patients with financial difficulties can approach the medical social workers to apply for the Medication Assistance Fund to help defray the cost of unsubsidised drugs, such as Iressa.
Karen Au Yong (Ms)
Deputy Director
Corporate Communications
Ministry of Health